Leveraging the potential of 1.0-mm i.d. columns in UHPLC-HRMS-based untargeted metabolomics

被引:0
|
作者
La Gioia, Danila [1 ,2 ]
Salviati, Emanuela [1 ]
Basilicata, Manuela Giovanna [3 ]
Felici, Claudia [4 ]
Botrugno, Oronza A. [4 ,5 ]
Tonon, Giovanni [4 ,5 ,6 ]
Sommella, Eduardo [1 ]
Campiglia, Pietro [1 ]
机构
[1] Univ Salerno, Dept Pharm, Via Giovanni Paolo II, SA, I-84084 Fisciano, Italy
[2] Univ Salerno, PhD Program Drug Discovery & Dev, Fisciano, SA, Italy
[3] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, I-80138 Naples, Italy
[4] IRCCS San Raffaele Sci Inst, Div Expt Oncol, Funct Genom Canc Unit, Milan, Italy
[5] Univ Vita Salute San Raffaele, Milan, Italy
[6] IRCCS San Raffaele Sci Inst, Ctr Omics Sci, Milan, Italy
关键词
Mass spectrometry; Metabolomics; Microbore; UHPLC; Untargeted; LIQUID-CHROMATOGRAPHY; PEAK-CAPACITY; MS; URINE;
D O I
10.1007/s00216-024-05588-z
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Untargeted metabolomics UHPLC-HRMS workflows typically employ narrowbore 2.1-mm inner diameter (i.d.) columns. However, the wide concentration range of the metabolome and the need to often analyze small sample amounts poses challenges to these approaches. Reducing the column diameter could be a potential solution. Herein, we evaluated the performance of a microbore 1.0-mm i.d. setup compared to the 2.1-mm i.d. benchmark for untargeted metabolomics. The 1.0-mm i.d. setup was implemented on a micro-UHPLC system, while the 2.1-mm i.d. on a standard UHPLC, both coupled to quadrupole-orbitrap HRMS. On polar standard metabolites, a sensitivity gain with an average 3.8-fold increase over the 2.1-mm i.d., along with lower LOD (LODavg 1.48 ng/mL vs. 6.18 ng/mL) and LOQ (LOQavg 4.94 ng/mL vs. 20.60 ng/mL), was observed. The microbore method detected and quantified all metabolites at LLOQ with respect to 2.1, also demonstrating good repeatability with lower CV% for retention times (0.29% vs. 0.63%) and peak areas (4.65% vs. 7.27%). The analysis of various samples, in both RP and HILIC modes, including different plasma volumes, dried blood spots (DBS), and colorectal cancer (CRC) patient-derived organoids (PDOs), in full scan-data dependent mode (FS-DDA) reported a significant increase in MS1 and MS2 features, as well as MS/MS spectral matches by 38.95%, 39.26%, and 18.23%, respectively. These findings demonstrate that 1.0-mm i.d. columns in UHPLC-HRMS could be a potential strategy to enhance coverage for low-amount samples while maintaining the same analytical throughput and robustness of 2.1-mm i.d. formats, with reduced solvent consumption.
引用
收藏
页数:11
相关论文
共 5 条
  • [1] The classification of almonds (Prunus dulcis) by country and variety using UHPLC-HRMS-based untargeted metabolomics
    Solsona, Gil R.
    Boix, C.
    Ibanez, M.
    Sancho, J. V.
    FOOD ADDITIVES AND CONTAMINANTS PART A-CHEMISTRY ANALYSIS CONTROL EXPOSURE & RISK ASSESSMENT, 2018, 35 (03): : 395 - 403
  • [2] UHPLC-HRMS-based tissue untargeted metabolomics study of naringin and hesperidin after dietary supplementation in chickens
    Baira, Eirini
    Dagla, Ioanna
    Siapi, Eleni
    Zoumpoulakis, Panagiotis
    Simitzis, Panagiotis
    Goliomytis, Michael
    Deligeorgis, Stelios G.
    Skaltsounis, Alexios-Leandros
    Gikas, Evagelos
    FOOD CHEMISTRY, 2018, 269 : 276 - 285
  • [3] Geographical discrimination of Flos Trollii by GC-MS and UHPLC-HRMS-based untargeted metabolomics combined with chemometrics
    Du, Qing-Yu
    He, Min
    Gao, Xin
    Yu, Xin
    Zhang, Jia-Ni
    Shi, Jie
    Zhang, Fang
    Lu, You-Yuan
    Wang, Han-Qing
    Yu, Yong-Jie
    Zhang, Xia
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2023, 234
  • [4] Serum Untargeted UHPLC-HRMS-Based Lipidomics to Discover the Potential Biomarker of Colorectal Advanced Adenoma
    Zhu, Yifan
    Wang, Lisheng
    Nong, Yanying
    Liang, Yunxiao
    Huang, Zongsheng
    Zhu, Pingchuan
    Zhang, Qisong
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8865 - 8878
  • [5] A novel UHPLC-HRMS-based metabolomics strategy enables the discovery of potential neuroactive metabolites in mice plasma, following i.p. administration of the main Crocus sativus L. bioactive component
    Karkoula, Evangelia
    Dagla, Ioanna-Valentini
    Baira, Eirini
    Kokras, Nikolaos
    Dalla, Christina
    Skaltsounis, Alexios-Leandros
    Gikas, Evagelos
    Tsarbopoulos, Anthony
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2020, 177